PTC Therapeutics board authorizes share repurchases of up to $500 million
PTCT•PTC Therapeutics' board authorized a share repurchase program covering up to $500 million of outstanding common stock, with purchases subject to market conditions and management's discretion.
1. Repurchase authorization
PTC Therapeutics' board authorized a program to repurchase up to $500 million of the company's outstanding common stock. Repurchases may occur from time to time, subject to market conditions and at management's discretion.
